$0.01
(Market cap
$13 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
0
P/B Ratio
1.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-13.7 %
-
ROCE
-- %
-
Industry P/E
37.32
-
EV/EBITDA
0.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-16.6
-
Face value
--
-
Shares outstanding
19,477,380
9 Years Aggregate
CFO
$-129.68 Mln
EBITDA
$-163.86 Mln
Net Profit
$-120.21 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
| -80.4 | 62.5 | -76.7 | -93.4 | -85.4 | -77.6 | -63.1 |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
| -92.2 | -86.6 | -19.0 | -43.0 | -61.1 | -12.9 | -12.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Moleculin Biotech (MBRX)
|
0.7 | 12.7 | 0.0 | -30.3 | -- | -228.1 | 0 | 1.2 |
| 17.7 | 6,109.1 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 190.1 | |
| 202.8 | 10,424.8 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 129.6 | |
| 76.6 | 14,974.8 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 113.4 | 12,310.3 | 830.8 | 54.9 | 3.2 | 8.1 | 264.8 | 17.9 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.1 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.3 | 5,591.7 | 290.5 | 197.2 | 82.5 | 19.9 | 28.9 | 5.9 | |
| 66.9 | 6,058.9 | 450.9 | 138.6 | 39.1 | 115.6 | 50.1 | 32.1 | |
| 132.1 | 8,865.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout Moleculin Biotech (MBRX)
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage... for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose that cut off the energy supply of tumors. The company was incorporated in 2015 and is headquartered in Houston, Texas. Read more
-
Founder, Chairman, President & CEO
Mr. Walter V. Klemp
-
Founder, Chairman, President & CEO
Mr. Walter V. Klemp
-
Headquarters
Houston, TX
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Moleculin Biotech (MBRX)
What is the current share price of Moleculin Biotech Inc (MBRX) Today?
The share price of Moleculin Biotech Inc (MBRX) is $0.65 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Moleculin Biotech Inc (MBRX) has given a return of -85.43% in the last 3 years.
What is the current PB & PE ratio of Moleculin Biotech Inc (MBRX)?
The P/E ratio of Moleculin Biotech Inc (MBRX) is 0.04 times as on 28-Aug-2026, a 100 discount to its peers’ median range of 37.32 times.
The P/B ratio of Moleculin Biotech Inc (MBRX) is 1.17 times as on 28-Aug-2026, a 85 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.32 |
0.71 |
2024 |
-0.01 |
0.04 |
2023 |
0.00 |
0.00 |
2022 |
0.00 |
0.00 |
2021 |
-0.01 |
0.00 |
What is the 52 Week High and Low of Moleculin Biotech Inc (MBRX)?
The 52-week high and low of Moleculin Biotech Inc (MBRX) are Rs 15.75 and Rs 0.16 as of 02-Sep-2026.
What is the market cap of Moleculin Biotech Inc (MBRX)?
Moleculin Biotech Inc (MBRX) has a market capitalisation of $ 13 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Moleculin Biotech Inc (MBRX)?
Before investing in Moleculin Biotech Inc (MBRX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.